Liver Elastography in Patients Undergoing Treatment for Hepatitis C

Status Recruiting

Clinical Trial Summary

According to the guidelines for treating hepatitis C livers stiffness (LS) measurement is equivalent to liver biopsy to prove grade-2 fibrosis or more by Metavir-score. Also flares of inflammation in other viral hepatitis (B) have been reported to increase the elastography measurements. There are very few reports so far on longitudinal data in a treatment cohort. In this study investigators will follow patients who undergo active treatment for hepatitis C virus (HCV). Investigators will collect longitudinal data of liver elastography and compare this to the current status of liver inflammation by blood samples. This may be important in order to know if transcutaneous US with elastography can be used as a tool to monitor active inflammation in liver disease and to quantify how much the inflammatory component contribute to LS and finally if it is possible to reverse not only inflammation but also liver fibrosis by treating viral hepatitis. Our aim is to assess shear wave elastography (SWE) and investigate if the method can be used, not only to define the indication for treatment through LS measurements, but also if LS due to inflammation and fibrosis may be reversible in treated patients. To investigate what role frequency of measurement obtains in follow up of patients with HCV play.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03434470
Study type	Observational
Source	Haukeland University Hospital
Contact	Anesa Mulabecirovic, MD
Phone	004793888212
Email	anesa.mulabecirovic@uib.no
Status	Recruiting
Phase	N/A
Start date	February 2, 2018
Completion date	November 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02487030` - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection	Phase 3
Active, not recruiting	`NCT05460130` - Implementing HCV Treatment for High-risk Populations in Austin, Texas	N/A
Completed	`NCT02220998` - Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection	Phase 3
Terminated	`NCT01052090` - Safety and Efficacy Study in Hepatitis C Patients With PHN121	Phase 1/Phase 2
Completed	`NCT02537379` - Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection	N/A
Recruiting	`NCT04156945` - Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men	N/A
Terminated	`NCT02510300` - A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
Withdrawn	`NCT04309734` - Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects	Phase 1/Phase 2
Active, not recruiting	`NCT04001608` - Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients	Phase 3
Completed	`NCT04112303` - Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis	Phase 3
Completed	`NCT02251717` - Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection	Phase 2
Recruiting	`NCT05092074` - Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
Recruiting	`NCT04005248` - Prevalence of HCV in HIV-negative MSM	N/A
Completed	`NCT02249182` - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection	Phase 2
Completed	`NCT02939989` - Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study	Phase 3
Completed	`NCT01718145` - A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects	Phase 3
Completed	`NCT01482611` - A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382	Phase 1
Completed	`NCT00255177` - Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	Phase 2
Terminated	`NCT02600351` - Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies	Phase 3
Completed	`NCT04980157` - CARES-HCV: Promoting Screening Uptake Among Diverse Baby Boomers